Quick Answer
GT Biopharma, Inc. reported Operating Income of -$12.42 million for fiscal year 2025.
GT Biopharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$12.42M | +13.5% |
| 2024 | -$14.36M | -5.8% |
| 2023 | -$13.58M | +36.1% |
| 2022 | -$21.26M | +63.0% |
| 2021 | -$57.52M | -750.3% |
| 2020 | -$6.76M | -142.1% |
| 2019 | $16.06M | +106.4% |
| 2018 | -$250.07M | -84.5% |
| 2017 | -$135.57M | -1346.2% |
| 2016 | -$9.37M | -5.0% |
| 2015 | -$8.93M | -272.6% |
| 2014 | -$2.40M | -202.1% |
| 2013 | -$793.0K | +77.4% |
| 2012 | -$3.51M | +10.5% |
| 2011 | -$3.93M | -57.3% |
| 2010 | -$2.50M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.38M | +6.2% | -123.5% |
| June 30, 2025 | -$1.51M | +61.3% | +21.7% |
| March 31, 2025 | -$1.93M | +37.5% | +46.4% |
| September 30, 2024 | -$3.60M | -15.4% | +7.7% |
| June 30, 2024 | -$3.91M | -7.9% | -26.4% |
| March 31, 2024 | -$3.09M | +15.7% | +1.0% |
| September 30, 2023 | -$3.12M | +55.5% | +13.8% |
| June 30, 2023 | -$3.62M | -20.1% | +1.2% |
- GT Biopharma, Inc. showed an increase of +13.5% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, GT Biopharma, Inc.’s operating income has declined by 397.5% (from -$2.50 million to -$12.42 million).
- The most recent figure is from GT Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: